NCT05779241View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

November 3, 2023

Study Completion Date

December 1, 2023

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

LYN-005

Risperidone long-acting oral capsule

DRUG

Risperidone

Risperidone immediate release (IR) oral tablets

Trial Locations (5)

30331

Atlanta Center for Medical Research, Atlanta

60640

Uptown Research Institute, Chicago

78754

Community Clinical Research, Inc., Austin

92845

CenExel CNS, Garden Grove

08053

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Lyndra Inc.

INDUSTRY